These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 15124702

  • 1. Evolution of BFM trials for childhood ALL.
    Schrappe M.
    Ann Hematol; 2004; 83 Suppl 1():S121-3. PubMed ID: 15124702
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M.
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [Abstract] [Full Text] [Related]

  • 5. [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)].
    Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G.
    Klin Padiatr; 1987; 199(3):151-60. PubMed ID: 3306129
    [Abstract] [Full Text] [Related]

  • 6. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 8. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
    Schrappe M.
    Radiat Prot Dosimetry; 2008 Jan 20; 132(2):130-3. PubMed ID: 19017727
    [Abstract] [Full Text] [Related]

  • 9. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 10. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004 Nov 01; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter.
    Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M.
    Klin Padiatr; 2001 Nov 01; 213(4):169-74. PubMed ID: 11528550
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
    Stanulla M, Cario G, Meissner B, Schrauder A, Möricke A, Riehm H, Schrappe M.
    Blood Cells Mol Dis; 2007 Nov 01; 39(2):160-3. PubMed ID: 17532236
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Zuna J, Hrusák O, Kalinová M, Muzíková K, Zörnerová T, Starý J, Trka J.
    Vnitr Lek; 2000 Aug 01; 46(8):465-9. PubMed ID: 11048511
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease.
    Steinemann D, Cario G, Stanulla M, Karawajew L, Tauscher M, Weigmann A, Göhring G, Ludwig WD, Harbott J, Radlwimmer B, Bartram C, Lichter P, Schrappe M, Schlegelberger B.
    Genes Chromosomes Cancer; 2008 Jun 01; 47(6):471-80. PubMed ID: 18311775
    [Abstract] [Full Text] [Related]

  • 20. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A.
    J Clin Oncol; 2009 Jul 10; 27(20):3363-9. PubMed ID: 19433688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.